Du är här


Moberg Pharma: Redeye: Moberg Pharma entering its peak season

Q1 in Moberg Pharma was below our expectations, but we remain on
course and made only minor changes to our forecasts after the report.
Main growth drivers (Dermoplast, Kerasal Nail and New Skin) have
shown no reason for concern in Q1'17, and will continue to be main
profit contributors, rendering a decline in the smaller brands less

We see good potential for the clinical asset MOB-015, with limited
development risk. At current share price levels, we believe the
market does not take this into account. Moberg Pharma is now entering
its peak season in terms of sales and profits (Q2'17 and Q3'17).
Continued solid performance in its OTC brands is a key catalyst for
share price development (3-6 months).

Read more and download the Research Update by Klas Palin:

Become a member at Redeye to access the latest research on Life
Science and Tech companies.

This is a press release from Redeye - Research Powered Investment
Banking. http://beta.redeye.se


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.